EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review



Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review



Clinical Therapeutics 31(7): 1497-1510



As a result of the reported efficacy of oral Bisphosphonates in reducing fractures, increasing bone mineral density (BMD), and reducing bone turnover, these agents are the recommended first line of treatment of postmenopausal osteoporosis. However, in clinical practice, patients might not be diagnosed or prescribed appropriate treatment. Even when bisphosphonates are prescribed, their therapeutic benefit may be compromised by poor treatment compliance and/or failure to persist with the treatment prescribed. New drugs or treatment regimens that reduce the risk for osteoporotic fractures and make the treatment of osteoporosis more convenient and suitable for patients are needed. The aims of the present review were to discuss the efficacy of monthly ibandronate in the treatment of postmenopausal osteoporosis and to determine treatment adherence with this drug. A search of MEDLINE (key terms: ibandronate and ibandronic acid; publication dates: 1996-December 2008) was used to identify studies of the efficacy and adherence of ibandronate in the treatment of postmenopausal osteoporosis. Additional searches were conducted to identify publications pertinent to compliance using the terms bisphosphonate and compliance. A total of 15 articles were included in the present review. An analysis of data from 2 US data-bases reported that once-monthly ibandronate was associated with significantly improved treatment persistence relative to weekly bisphosphonates at 1 year. In BONE (Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe), the risk for new vertebral fractures was reduced by 62% with oral ibandronate 2.5 mg/d versus placebo (P < 0.001) at 3 years. In the 2-year MOBILE (Monthly Oral Ibandronate in Ladies) study, oral ibandronate 150 mg once monthly was associated with significantly increased lumbar spine BMD (P < 0.001), and bone turnover markers were numerically decreased compared with the daily regimen. A meta-analysis reported a 38% lower risk for nonvertebral fractures with combined high doses of ibandronate (including oral iban-dronate 150 mg monthly and ibandronate 3 mg IV every 3 months) compared with oral ibandronate 2.5 mg/d (change in annual cumulative exposure, from > or =10.8 to 5.5 mg). Based on the findings from the studies included in the present review, treatment with oral ibandronate 150 mg once monthly was reported to be at least as effective as the daily regimen and was associated with increased adherence. Monthly iban-dronate might provide an option for the treatment of postmenopausal osteoporosis.

(PDF emailed within 0-6 h: $19.90)

Accession: 054744084

Download citation: RISBibTeXText

PMID: 19695399

DOI: 10.1016/j.clinthera.2009.07.018



Related references

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. Clinical Therapeutics 31(4): 751-761, 2009

Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Korean Journal of Internal Medicine 26(3): 340-347, 2012

Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis. Therapeutics and Clinical Risk Management 2(1): 3-18, 2008

Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis. Osteoporosis International 26(11): 2685-2693, 2016

The BALTO II study: Patient preference for once-monthly oral ibandronate and weekly oral alendronate in postmenopausal osteoporosis. 2006

Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen. Clinical Therapeutics 28(4): 475-490, 2006

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. Journal of Bone and Mineral Research 20(8): 1315-1322, 2005

Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). Joint, Bone, Spine 75(3): 303-310, 2007

Similar improvements in hip bone mineral density with monthly oral ibandronate (150mg) versus weekly oral alendronate (70mg) in postmenopausal osteoporosis. 2007

Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. Journal of Clinical Endocrinology and Metabolism 94(1): 171-180, 2008

Response to once-monthly and daily oral ibandronate in women with postmenopausal osteoporosis: 2-year findings from mobile. 2006

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Annals of the Rheumatic Diseases 65(5): 654-661, 2005

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study (vol 65, pg 654, 2006). 2008

Impact of oral ibandronate 15mg once monthly on bone structure and density in postmenopausal osteoporosis or osteopenia derived from in vivo ?CT. 2011